Lyophilized ophthalmologic patches as novel corneal drug formulations using a semi-solid extrusion 3D printer
Lyophilized ophthalmologic patches as novel corneal drug formulations using a semi-solid extrusion 3D printer
复制标题
DOI：
10.1016/j.ijpharm.2022.121448
复制
发表时间：
2022-02-23
影响因子：
5.8
通讯作者：
Ozeki, Tetsuya
中科院分区：
文献类型：
--
作者：
Tagami, Tatsuaki;Goto, Eiichi;Ozeki, Tetsuya
3D打印技术是一种新颖而实用的方法，用于生产独特而复杂的工业和医疗物品。在制药领域，美国食品和药物管理局批准3D打印片剂，导致其他3D打印药物配方和剂型被提出和研究。在这里，我们报告了一种新型的眼科贴片，用于控制药物释放，使用半固体材料挤出型3D打印机制造。使用由羟丙纤维素（HPMC）、糖醇（甘露醇、木糖醇）和药物组成的水凝胶打印机墨水3D打印斑块状物体，然后冷冻干燥。打印机油墨和贴片的黏性与HPMC和糖醇浓度有关。然后，对冻干贴片的物理性质、表面结构、吸水性、抗菌活性和药物释放谱进行了表征。制备了不同剂量、不同样式的冻干眼科贴片，作为医院个性化治疗的模型。然后，使用市售滴眼液配方制备含有多种药物的眼科贴片。目前的研究表明，3D打印适用于生产新的剂型，因为它的高灵活性允许在临床环境中制备患者定制的剂量。
3D printing technology is a novel and practical approach for producing unique and complex industrial and medical objects. In the pharmaceutical field, the approval of 3D printed tablets by the US Food and Drug Administration has led to other 3D printed drug formulations and dosage forms being proposed and investigated. Here, we report novel ophthalmologic patches for controlled drug release fabricated using a semi-solid material extrusion-type 3D printer. The patch-shaped objects were 3D printed using hydrogel-based printer inks composed of hypromellose (HPMC), sugar alcohols (mannitol, xylitol), and drugs, then freeze-dried. The viscous properties of the printer inks and patches were dependent on the HPMC and sugar alcohol concentrations. Then, the physical properties, surface structure, water uptake, antimicrobial activity, and drug release profile of lyophi-lized patches were characterized. Lyophilized ophthalmologic patches with different dosages and patterns were fabricated as models of personalized treatments prepared in hospitals. Then, ophthalmologic patches containing multiple drugs were fabricated using commercially available eye drop formulations. The current study indicates that 3D printing is applicable to producing novel dosage forms because its high flexibility allows the preparation of patient-tailored dosages in a clinical setting.